Physician
Kay, Paul
Kay, Paul was paid $8.58M by Medicaid between Jan 2018 and Dec 2024, across 234 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 13% of everything it billed.
33Billing provider infoKAY, PAUL
SPRINGFIELD, IL 62769
SPRINGFIELD, IL 62769
33aNPI1780611566assigned 06/27/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$8.58M
24GClaims1,203,640
24DCodes billed234
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#4 of 398
Median peer was paid$66K
This provider vs. median131×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 109,007 | $561K | |
| 2019 | 200,580 | $1.09M | |
| 2020 | 232,483 | $1.51M | |
| 2021 | 184,106 | $1.60M | |
| 2022 | 107,635 | $1.00M | |
| 2023 | 181,929 | $1.51M | |
| 2024incomplete | 187,900 | $1.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 13% | 6,399 | 5,630 | $1.08M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.8% | 24,391 | 18,210 | $671K |
| 80053 | Comprehensive metabolic panel | 5.7% | 96,690 | 63,267 | $488K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.9% | 12,500 | 10,287 | $422K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 4.6% | 8,026 | 7,093 | $397K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.5% | 135,278 | 81,252 | $383K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.7% | 11,087 | 10,297 | $234K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.7% | 11,097 | 10,310 | $234K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.4% | 51,093 | 25,233 | $208K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.0% | 21,990 | 18,678 | $175K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.9% | 4,197 | 3,616 | $163K |
| 87581 | 1.8% | 6,979 | 6,159 | $154K |
222 more codes
| 87486 | 1.8% | 6,975 | $154K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.7% | 28,661 | $145K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.7% | 4,147 | $144K |
| 87040 | 1.7% | 13,067 | $143K | |
| 83735 | 1.6% | 41,888 | $140K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 10,553 | $130K |
| 82805 | 1.5% | 5,736 | $130K | |
| 82948 | 1.4% | 44,311 | $121K | |
| 84484 | 1.3% | 26,582 | $116K | |
| 83880 | 1.2% | 9,524 | $99K | |
| 82803 | 1.1% | 9,160 | $96K | |
| 87507 | 1.1% | 562 | $95K | |
| 87430 | 1.0% | 11,838 | $89K | |
| 83605 | <1% | 16,036 | $83K | |
| 83690 | <1% | 24,691 | $81K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,817 | $70K |
| 87641 | <1% | 3,213 | $70K | |
| 82330 | <1% | 7,056 | $61K | |
| 87480 | <1% | 5,063 | $59K | |
| 85027 | <1% | 20,928 | $59K | |
| 87510 | <1% | 4,920 | $57K | |
| 85610 | <1% | 28,534 | $55K | |
| 84702 | <1% | 12,383 | $55K | |
| 87653 | <1% | 2,365 | $52K | |
| 87186 | <1% | 8,802 | $50K | |
| 85730 | <1% | 15,613 | $49K | |
| 86901 | <1% | 20,347 | $48K | |
| 86850 | <1% | 15,244 | $44K | |
| 87660 | <1% | 5,258 | $40K | |
| 81001 | <1% | 30,666 | $40K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,195 | $40K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,179 | $39K |
| 81025 | <1% | 19,322 | $39K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,922 | $39K |
| 86900 | <1% | 20,342 | $37K | |
| 88307 | <1% | 599 | $36K | |
| 86780 | <1% | 4,501 | $36K | |
| 80061 | Lipid panel | <1% | 10,834 | $36K |
| 84100 | <1% | 16,295 | $35K | |
| 85379 | <1% | 9,199 | $34K | |
| 87797 | <1% | 2,738 | $33K | |
| 86803 | <1% | 3,945 | $32K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,007 | $28K |
| 84439 | <1% | 6,348 | $27K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,842 | $27K |
| 80202 | <1% | 4,051 | $27K | |
| 87340 | <1% | 3,907 | $25K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,234 | $24K |
| 81003 | <1% | 23,216 | $24K | |
| 82550 | <1% | 8,226 | $24K | |
| 80076 | <1% | 6,772 | $23K | |
| 87081 | <1% | 8,317 | $23K | |
| 86140 | <1% | 9,653 | $22K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,006 | $19K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,755 | $19K |
| 80074 | <1% | 1,001 | $19K | |
| 87070 | <1% | 6,096 | $18K | |
| 82728 | <1% | 4,724 | $18K | |
| 82607 | <1% | 3,105 | $18K | |
| 87088 | <1% | 3,439 | $17K | |
| 82247 | <1% | 8,069 | $17K | |
| 80306 | <1% | 2,997 | $16K | |
| 87420 | <1% | 2,163 | $16K | |
| 85007 | <1% | 9,490 | $16K | |
| 82248 | <1% | 7,968 | $16K | |
| 87205 | <1% | 6,954 | $14K | |
| 83615 | <1% | 4,636 | $13K | |
| 84703 | <1% | 3,757 | $13K | |
| 83550 | <1% | 3,028 | $12K | |
| 83540 | <1% | 3,584 | $11K | |
| 86880 | <1% | 3,822 | $11K | |
| 82150 | <1% | 3,335 | $10K | |
| 84481 | <1% | 2,204 | $10K | |
| 86762 | <1% | 2,383 | $10K | |
| 82565 | <1% | 4,516 | $9K | |
| 82746 | <1% | 1,664 | $9K | |
| 85014 | <1% | 7,917 | $9K | |
| 80069 | <1% | 2,127 | $9K | |
| 87481 | <1% | 831 | $9K | |
| 84550 | <1% | 4,290 | $9K | |
| 84295 | <1% | 3,805 | $9K | |
| 82140 | <1% | 1,953 | $8K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 217 | $8K |
| 86787 | <1% | 1,137 | $8K | |
| 86038 | <1% | 1,080 | $8K | |
| 84132 | <1% | 3,978 | $8K | |
| 82570 | <1% | 3,613 | $8K | |
| 85520 | <1% | 1,427 | $7K | |
| 87493 | <1% | 404 | $7K | |
| 82553 | <1% | 1,649 | $7K | |
| 86592 | <1% | 3,380 | $7K | |
| 85652 | <1% | 4,870 | $6K | |
| 84460 | <1% | 2,693 | $6K | |
| 82962 | <1% | 4,171 | $6K | |
| 84450 | <1% | 2,639 | $6K | |
| 87184 | <1% | 1,214 | $6K | |
| 87075 | <1% | 756 | $5K | |
| 82784 | <1% | 841 | $5K | |
| 86870 | <1% | 631 | $5K | |
| 83970 | <1% | 325 | $5K | |
| 85384 | <1% | 1,612 | $5K | |
| 86225 | <1% | 863 | $5K | |
| 84112 | <1% | 235 | $5K | |
| 87077 | <1% | 3,602 | $5K | |
| 87522 | Neg quan hep c or qual rna | <1% | 186 | $5K |
| 87147 | <1% | 2,188 | $5K | |
| 85046 | <1% | 1,767 | $5K | |
| 86920 | <1% | 975 | $4K | |
| 85018 | <1% | 4,222 | $4K | |
| 80081 | <1% | 120 | $4K | |
| 82010 | <1% | 1,830 | $4K | |
| 80050 | General health panel | <1% | 201 | $4K |
| 86922 | <1% | 379 | $4K | |
| 86480 | <1% | 158 | $4K | |
| 87807 | <1% | 819 | $4K | |
| 84146 | <1% | 598 | $4K | |
| 80051 | <1% | 1,308 | $4K | |
| 87015 | <1% | 937 | $4K | |
| 87400 | <1% | 451 | $4K | |
| 83516 | <1% | 632 | $3K | |
| 84403 | <1% | 279 | $3K | |
| 81513 | <1% | 106 | $3K | |
| 82533 | <1% | 391 | $3K | |
| 86885 | <1% | 1,129 | $3K | |
| 82105 | <1% | 423 | $3K | |
| 86706 | <1% | 478 | $3K | |
| 87449 | <1% | 415 | $3K | |
| 82375 | <1% | 1,018 | $3K | |
| 86003 | <1% | 154 | $3K | |
| 80164 | <1% | 683 | $3K | |
| 84156 | <1% | 2,823 | $3K | |
| 83001 | <1% | 314 | $3K | |
| 84145 | <1% | 633 | $3K | |
| 82310 | <1% | 1,412 | $3K | |
| 89051 | <1% | 751 | $2K | |
| 83021 | <1% | 395 | $2K | |
| 82950 | <1% | 947 | $2K | |
| 87210 | <1% | 1,216 | $2K | |
| 87102 | <1% | 543 | $2K | |
| 84520 | <1% | 1,331 | $2K | |
| 83655 | <1% | 319 | $2K | |
| 83050 | <1% | 898 | $2K | |
| 84466 | <1% | 445 | $2K | |
| 84030 | <1% | 638 | $2K | |
| 84300 | <1% | 749 | $2K | |
| 87324 | <1% | 185 | $1K | |
| 84478 | <1% | 613 | $1K | |
| 87116 | <1% | 197 | $1K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 134 | $1K |
| 87206 | <1% | 391 | $1K | |
| 82043 | <1% | 598 | $1K | |
| 86704 | <1% | 146 | $1K | |
| 85347 | <1% | 333 | $1K | |
| 82785 | <1% | 241 | $1K | |
| 86308 | <1% | 420 | $969.60 | |
| 83930 | <1% | 342 | $964.28 | |
| 88342 | <1% | 54 | $924.31 | |
| 88141 | <1% | 72 | $840.02 | |
| 87181 | <1% | 135 | $838.68 | |
| 86769 | <1% | 38 | $800.62 | |
| 88304 | <1% | 43 | $795.33 | |
| 82945 | <1% | 496 | $783.44 | |
| 83935 | <1% | 301 | $711.17 | |
| 84157 | <1% | 526 | $631.35 | |
| 87808 | <1% | 71 | $536.44 | |
| 81329 | <1% | 15 | $504.00 | |
| 87899 | <1% | 62 | $503.95 | |
| 86698 | <1% | 24 | $472.70 | |
| 86431 | <1% | 131 | $466.98 | |
| 83010 | <1% | 100 | $438.57 | |
| 83002 | <1% | 66 | $367.46 | |
| 85049 | <1% | 520 | $360.50 | |
| 80177 | <1% | 66 | $317.40 | |
| 84155 | <1% | 257 | $307.78 | |
| 87529 | <1% | 12 | $297.70 | |
| 85651 | <1% | 127 | $294.40 | |
| 86147 | <1% | 15 | $285.75 | |
| 82977 | <1% | 116 | $283.75 | |
| 86940 | <1% | 87 | $282.56 | |
| 82657 | <1% | 15 | $279.30 | |
| 87254 | <1% | 46 | $278.40 | |
| 86645 | <1% | 29 | $264.48 | |
| 83883 | <1% | 35 | $255.78 | |
| 81002 | <1% | 221 | $218.40 | |
| 82947 | <1% | 198 | $208.40 | |
| 85660 | <1% | 69 | $172.42 | |
| 83090 | <1% | 24 | $158.40 | |
| 84075 | <1% | 118 | $158.22 | |
| 86160 | <1% | 18 | $157.09 | |
| 86336 | <1% | 14 | $152.18 | |
| 80185 | <1% | 24 | $149.27 | |
| 82172 | <1% | 22 | $131.84 | |
| 87176 | <1% | 31 | $130.90 | |
| 82272 | <1% | 101 | $129.20 | |
| 86703 | <1% | 12 | $120.12 | |
| 82436 | <1% | 51 | $111.78 | |
| 85461 | <1% | 49 | $110.29 | |
| 87185 | <1% | 41 | $109.80 | |
| 84133 | <1% | 52 | $109.14 | |
| 83721 | <1% | 57 | $107.41 | |
| 86376 | <1% | 24 | $102.82 | |
| 83520 | <1% | 12 | $101.44 | |
| 85613 | <1% | 29 | $95.30 | |
| 86644 | <1% | 15 | $93.38 | |
| 87045 | <1% | 18 | $92.25 | |
| 87427 | <1% | 18 | $87.50 | |
| 83993 | <1% | 14 | $86.38 | |
| 84153 | <1% | 14 | $85.80 | |
| 82042 | <1% | 36 | $83.32 | |
| 87450 | <1% | 16 | $82.40 | |
| 83695 | <1% | 20 | $81.40 | |
| 82677 | <1% | 14 | $70.84 | |
| 80178 | <1% | 20 | $61.37 | |
| 84480 | <1% | 13 | $52.58 | |
| 85045 | <1% | 44 | $47.16 | |
| 84436 | <1% | 14 | $43.68 | |
| 84134 | <1% | 13 | $36.27 | |
| 82040 | <1% | 20 | $18.95 | |
| 87046 | <1% | 18 | $16.80 | |
| 80320 | 0% | 165 | $0.00 | |
| 86923 | 0% | 312 | $0.00 | |
| 87150 | 0% | 102 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.